Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells.

The use of tumor cells as vaccines in cancer immunotherapy is critically dependent on their capacity to initiate and amplify tumor-specific immunity. Optimal responses may require the modification of the tumor cells not only to increase their immunogenicity but also to improve their ability to recruit effector cells to the tumor sites or sites of tumor antigen exposure. It has been reported that CD40 cross-linking of acute lymphoblastic leukemia (ALL) cells significantly increases their immunogenicity and allows the generation and expansion of autologous antileukemia cytotoxic T lymphocytes. This study demonstrates that the CD40 ligation of these tumor cells also induces the secretion of the CC-chemokines MDC and TARC. Supernatants from malignant cells cultured in the presence of sCD40L promote the migration of activated T cells that express CCR4, the common specific receptor for MDC and TARC. More importantly, the supernatants from CD40-stimulated tumor cells also support the transendothelial migration of autologous CCR4(+) antileukemia T cells. Therefore, the results demonstrate that the delivery to leukemia cells of a single physiologic signal, that is, CD40 cross-linking, simultaneously improves tumor cell immunogenicity and induces potent chemoattraction for T cells. (Blood. 2001;98:533-540)

[1]  P. Anderson,et al.  Dependency on intercellular adhesion molecule recognition and local interleukin-2 provision in generation of an in vivo CD8+ T-cell immune response to murine myeloid leukemia. , 1995, Blood.

[2]  A. Mantovani,et al.  Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. , 1998, Journal of immunology.

[3]  K. Matsushima,et al.  Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. , 1999, International immunology.

[4]  D. Pardoll.  Paracrine cytokine adjuvants in cancer immunotherapy. , 1995, Annual review of immunology.

[5]  J. Banchereau,et al.  Activation of human dendritic cells through CD40 cross-linking , 1994, The Journal of experimental medicine.

[6]  Steffen Jung,et al.  Chemokine receptors in lymphoid organ homeostasis. , 1999, Current opinion in immunology.

[7]  Bruce L. Levine,et al.  Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation , 1996, Science.

[8]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[9]  L. Kwak,et al.  Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity , 1999, Nature Biotechnology.

[10]  J. Gribben,et al.  Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. , 1997, Blood.

[11]  P. Kiener,et al.  Expression of functional CD40 by vascular endothelial cells , 1995, The Journal of experimental medicine.

[12]  D. Schadendorf,et al.  The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice , 1999, British Journal of Cancer.

[13]  A. Huber,et al.  Regulation of transendothelial neutrophil migration by endogenous interleukin-8. , 1991, Science.

[14]  K. Matsushima,et al.  Serial analysis of gene expression in human monocyte-derived dendritic cells. , 1999, Blood.

[15]  S. Ostrand-Rosenberg.  Tumor immunotherapy: the tumor cell as an antigen-presenting cell. , 1994, Current opinion in immunology.

[16]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[17]  P. Gray,et al.  Macrophage-derived Chemokine Is a Functional Ligand for the CC Chemokine Receptor 4* , 1998, The Journal of Biological Chemistry.

[18]  F. Sallusto,et al.  Three chemokines with potential functions in T lymphocyte‐independent and ‐dependent B lymphocyte stimulation , 1999, European journal of immunology.

[19]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[20]  L. Glimcher,et al.  Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice , 1995, The Journal of experimental medicine.

[21]  S. Burdach,et al.  Combined chemokine and cytokine gene transfer enhances antitumor immunity , 1996, Nature Medicine.

[22]  H. Spits,et al.  CD40 expressed on thymic epithelial cells provides costimulation for proliferation but not for apoptosis of human thymocytes. , 1996, Journal of immunology.

[23]  C. Mackay,et al.  Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. , 1998, Immunology today.

[24]  M. Baggiolini.  Chemokines and leukocyte traffic , 1998, Nature.

[25]  Laura A Hanyok,et al.  Cell‐based vaccines for the stimulation of immunity to metastatic cancers , 1999, Immunological reviews.

[26]  A. Hartmann,et al.  Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. , 1999, The American journal of pathology.

[27]  C. Mackay,et al.  Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes , 1998, The Journal of experimental medicine.

[28]  C. Schaniel,et al.  The Role of Chemokines in Regulating Cell Migration during Humoral Immune Responses , 1999, Cell.

[29]  S. Ma,et al.  Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. , 1998, Journal of immunology.

[30]  S. Sallan,et al.  Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. , 1999, Blood.

[31]  Y. Yazaki,et al.  Expression of costimulatory molecules in human leukemias. , 1996, Leukemia.

[32]  Christoph Schaniel,et al.  Activated Murine B Lymphocytes and Dendritic Cells Produce a Novel CC Chemokine which Acts Selectively on Activated T Cells , 1998, The Journal of experimental medicine.

[33]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[34]  M. Halterman,et al.  Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. , 1999, Blood.

[35]  H. Miller.  Gene Therapy on Trial , 2000, Science.

[36]  O. Yoshie,et al.  The T Cell-directed CC Chemokine TARC Is a Highly Specific Biological Ligand for CC Chemokine Receptor 4* , 1997, The Journal of Biological Chemistry.

[37]  R. Schwabe,et al.  CD40 function in nonhematopoietic cells. Nuclear factor kappa B mobilization and induction of IL-6 production. , 1995, Journal of immunology.

[38]  K. Matsushima,et al.  Serial analysis of gene expression in human monocytes and macrophages. , 1999, Blood.

[39]  A. Cardoso.  Antitumor Immunity as Therapy for Human Cancer , 2000 .

[40]  G. Freeman,et al.  B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. , 1996, Journal of immunology.

[41]  M. Rocchi,et al.  The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. , 1998, Journal of immunology.

[42]  I. Witz,et al.  MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells. , 1999, Immunology letters.

[43]  F. Sallusto,et al.  The role of chemokine receptors in directing traffic of naive, type 1 and type 2 T cells. , 1999, Current topics in microbiology and immunology.

[44]  L. Chess,et al.  Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals , 1995, The Journal of experimental medicine.

[45]  A. Lanzavecchia,et al.  Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation , 1993, The Journal of experimental medicine.

[46]  J. Gribben,et al.  Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. , 1996, Blood.

[47]  P. Allavena,et al.  Human Macrophage–derived Chemokine (mdc), a Novel Chemoattractant for Monocytes, Monocyte-derived Dendritic Cells, and Natural Killer Cells , 1997 .

[48]  A. Mantovani,et al.  The chemokine system: redundancy for robust outputs. , 1999, Immunology today.

[49]  J. Gribben,et al.  Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. , 1994, Blood.

[50]  G. Dranoff,et al.  Gene transfer as cancer therapy. , 1995, Advances in immunology.

[51]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[52]  T. Springer,et al.  Characterization of transendothelial chemotaxis of T lymphocytes. , 1995, Journal of immunological methods.

[53]  H. Niitani,et al.  Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity. , 1992, Cancer research.